Key players in the market are involved in various business strategies such as research and development, in order to gain competitive edge in the global market. For instance, in July 2019, Eli Lilly and Company, a U.S.-based pharmaceutical company, announced positive results for Verzenio (abemaciclib), which demonstrated significant improvement in overall survival of Phase 3 MONARCH 2 clinical trial. Verzenio is indicated for the treatment of advanced or metastatic breast cancer.
Key companies in the market are involved in different growth strategies such as gaining product approval from regulatory authorities, in order to expand their product portfolio and enhance their market presence. For instance, in July 2019, Eisai Co., Ltd., a Japanese pharmaceutical company, received New Drug Approval for its anticancer agent Halaven (eribulin mesylate) from China National Medical Products Administration (NMPA), which is indicated for the use people suffering from metastatic or locally advanced breast cancer.
Key companies in the market are focused on different growth strategies such as gaining product approval from regulatory authorities, in order to expand their product portfolio and gain competitive edge in the global market. For instance, in August 2019, Roche AG received product approval for Tecentriq (atezolizumab) plus chemotherapy (Abraxane [paclitaxel protein-bound particles for injectable suspension (albumin-bound); nab-paclitaxel]) from European Commission. This is indicated for the patients with metastatic or unresectable locally advanced triple negative breast cancer.